leadf
logo-loader
viewFrontier IP Group PLC

Frontier IP portfolio firm The Vaccine Group inks collaboration deal to tackle diseases in pigs

The collaboration will work to develop a vaccine for porcine respiratory and reproductive syndrome virus, one of the most economically damaging diseases in the global pig industry

Frontier IP Group PLC - Frontier IP portfolio firm The Vaccine Group inks collaboration deal to tackle diseases in pigs

Frontier IP Group PLC (LON:FIPP) said its portfolio firm, The Vaccine Group (TVG), has signed a collaboration deal with the Pirbright Institute and ECO Animal Health Group PLC (LON:EAH) to develop a vaccine to combat porcine respiratory and reproductive syndrome virus (PRRSV), one of the most economically damaging diseases in the global pig industry.

Under the terms of the deal, ECO Animal Health will fund an 18-month development project that will see TVG use its novel vaccine technology as a platform for two prototype PRRSV vaccines. Meanwhile, Pirbright, a world leading centre of excellence in controlling viral diseases of livestock and viruses that spread from animal to humans, will supply the PRRSV genes and conduct animal trials for the vaccines to test their effectiveness.

READ: Frontier IP hails portfolio company's cauliflower harvesting collaboration with Bonduelle

The vaccines will be created by inserting non-infectious conserved genes from PRRSV into a benign herpesvirus, which then stimulates the immune system when delivered into animals. Vaccines that use herpesviruses as their base have been shown to provoke particularly strong reactions from T cells, which are a vital part of the antiviral response.

PRRSV costs European pig farmers an estimated €1.5bn per year and around US$600mln for the American pig industry.

“This is an exciting opportunity that brings together critical basic science and translational expertise towards addressing this major infectious disease in pigs.  As PRRSV is a member of the Nidovirus group of viruses, a group that also contains [COVID-19], what we learn from development of a PRRSV vaccine may also help inform our development of a vaccine against [COVID-19]", TVG founder and chief scientific officer Michael Jarvis said in a statement.

"This collaboration with The Pirbright Institute and ECO Animal Health provides a strong endorsement for the potential of The Vaccine Group's novel vaccine platform technology. The company has made very good progress this year, and we are delighted it continues to go from strength to strength", added Frontier IP’s chief commercialisation officer Matthew White.

Quick facts: Frontier IP Group PLC

Price: 66 GBX

AIM:FIPP
Market: AIM
Market Cap: £36.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Frontier IP Group PLC chief sees first investee IPO by the end of 2017

Neil Crabb, chief executive of Frontier IP Group PLC (LON:FIPP) says a number of its investee companies “are beginning to see significant commercial traction now.” In terms of an upcoming IPO for any of its investee firms, he says: “There are a number of companies in the portfolio...

on 03/09/2016

2 min read